Last updated: July 31, 2026
Idamycin is the brand name for idarubicin hydrochloride, an anthracycline chemotherapy used primarily with cytarabine for adults with acute myeloid leukemia (AML). Its U.S. product is a mature injectable medicine with no meaningful remaining originator exclusivity, extensive generic competition, and limited prospects for brand-led growth. Clinical development has shifted from Idamycin itself to idarubicin-containing AML regimens and combinations with targeted agents.
The commercial outlook is stable to declining in value. Volume should remain supported by AML treatment demand, hospital protocols and use in countries where idarubicin remains a standard anthracycline. Price erosion, generic substitution and competition from daunorubicin, liposomal daunorubicin/cytarabine, venetoclax-based regimens and newer AML therapies will limit revenue growth.
What is Idamycin and what is idarubicin used for?
Idamycin PFS contains idarubicin hydrochloride, an anthracycline that inhibits topoisomerase II and disrupts DNA replication. The U.S. Food and Drug Administration approved idarubicin in combination with cytarabine for induction therapy in adults with AML, including patients who have not previously received treatment and patients with relapsed or refractory disease in appropriate clinical settings.[1]
The marketed U.S. dosage form is an intravenous solution supplied in single-dose vials. Idarubicin is administered in specialized oncology settings because of its myelosuppressive, cardiotoxic and vesicant properties.
| Attribute |
Idamycin / idarubicin |
| Active ingredient |
Idarubicin hydrochloride |
| Therapeutic class |
Anthracycline antineoplastic |
| Primary indication |
Acute myeloid leukemia |
| U.S. route |
Intravenous |
| Common regimen |
Idarubicin plus cytarabine |
| Originator brand |
Idamycin PFS |
| U.S. approval |
1990 |
| Regulatory pathway |
New drug application |
| Main competitors |
Daunorubicin, cytarabine combinations, CPX-351, venetoclax-based regimens |
| Biosimilar exposure |
Not applicable; idarubicin is a small molecule |
| Generic exposure |
High |
The FDA label identifies cumulative anthracycline cardiomyopathy as a major safety concern. Severe myelosuppression, infection, tumor lysis, extravasation injury and secondary malignancies are also clinically relevant risks.[1]
What clinical trials are evaluating Idamycin and idarubicin?
Current clinical research evaluates idarubicin as a component of AML chemotherapy rather than as a standalone branded product. Idamycin is not typically the commercial identity used in trial registries. Studies generally list the active ingredient, idarubicin, or describe a treatment backbone such as “7+3.”
Idarubicin in intensive AML induction
The standard intensive AML backbone combines an anthracycline administered for several days with continuous-infusion cytarabine. Idarubicin and daunorubicin are the principal anthracyclines used in this setting.
Clinical studies have compared:
- Idarubicin versus daunorubicin in induction therapy.
- Different anthracycline dose levels.
- Idarubicin-cytarabine regimens followed by consolidation.
- Idarubicin combinations with fludarabine, granulocyte colony-stimulating factor or other chemotherapy agents.
- Idarubicin-based salvage regimens for relapsed or refractory AML.
A randomized comparison published in the National Cancer Institute-supported AML literature found that idarubicin-based induction could produce favorable remission outcomes relative to conventional daunorubicin-based therapy in selected adult AML populations.[2] Results vary by age, cytogenetic risk, molecular subtype, dose intensity and post-remission treatment.
Idarubicin in relapsed and refractory AML
Idarubicin remains part of multi-agent salvage regimens, including combinations with cytarabine and other cytotoxic agents. Its use has declined in some treatment centers because relapsed AML treatment now includes targeted therapies such as gilteritinib, ivosidenib, enasidenib and venetoclax-based combinations, depending on biomarker status and prior therapy.
Idarubicin and targeted-agent combinations
Clinical research has tested anthracycline-cytarabine backbones with targeted therapies. Relevant development areas include:
- Venetoclax added to intensive induction or salvage therapy.
- FLT3 inhibitors in FLT3-mutated AML.
- IDH1 or IDH2 inhibitors in biomarker-selected disease.
- Antibody and antibody-drug-conjugate combinations.
- Post-remission maintenance approaches.
The competitive trend is toward molecularly defined regimens. Idarubicin is most defensible where intensive chemotherapy remains appropriate and where the treating center retains an established idarubicin-based protocol.
What is the FDA regulatory status of Idamycin?
Idamycin PFS is an FDA-approved prescription oncology product. The approved U.S. indication is combination therapy with cytarabine for adult AML.[1]
The product label contains boxed or prominent warnings relating to:
- Severe myelosuppression.
- Cardiotoxicity and potentially irreversible congestive heart failure.
- Extravasation and local tissue necrosis.
- Secondary acute myeloid leukemia and myelodysplastic syndrome.
- Tumor lysis syndrome.
- Hepatic impairment and dose management.
Idarubicin is generally administered by hospitals, academic cancer centers and specialist oncology clinics. It is not a retail pharmacy product in the ordinary sense. Demand therefore depends on institutional formulary decisions, group purchasing contracts, generic availability and national oncology guidelines.
What is the Orange Book status of Idamycin?
The principal U.S. commercial issue is generic substitution, not originator patent enforcement. Idarubicin has been available as a generic injectable for many years. The active ingredient is an established small molecule, and the original patent and regulatory exclusivity periods expired long ago.
| Exclusivity issue |
Idamycin status |
| New chemical entity exclusivity |
Expired |
| Original compound patent |
Expired |
| Pediatric exclusivity |
No current commercial significance |
| Orphan-drug exclusivity |
No current exclusivity barrier |
| Formulation exclusivity |
No commercially meaningful barrier identified |
| Generic injectable competition |
Established |
| Biosimilar pathway |
Not applicable |
The FDA Orange Book should be checked for the current marketing status of individual idarubicin abbreviated new drug applications, including discontinued or active listings. The existence of an approved generic application is more commercially significant than any residual Idamycin brand position.[3]
What patents protect Idamycin?
No enforceable originator patent estate is expected to protect the core Idamycin product in the United States. Idarubicin was discovered and commercialized decades ago. Any original composition-of-matter, preparation or use patents associated with the drug have expired.
Potential patent categories historically associated with idarubicin include:
- The idarubicin compound and salt.
- Chemical synthesis and purification methods.
- Injectable formulations.
- Treatment methods involving AML or other malignancies.
- Combination regimens with cytarabine or additional chemotherapy.
These categories do not create a meaningful current barrier to generic idarubicin injection. Later patents covering specific manufacturing methods or narrow combinations could affect individual suppliers, but they would not restore broad Idamycin exclusivity.
How strong is the Idamycin patent estate?
The current patent estate is weak from a commercial defense perspective.
| Patent factor |
Assessment |
| Core molecule protection |
Expired |
| Broad AML method-of-use protection |
Expired or commercially ineffective |
| Injectable formulation protection |
No meaningful broad barrier |
| Manufacturing protection |
Potentially supplier-specific |
| Paragraph IV exposure |
Low strategic relevance because the product is already generic |
| Litigation leverage |
Limited |
| Generic launch risk |
High |
Are there Paragraph IV challenges to Idamycin?
Paragraph IV litigation is not the primary competitive mechanism for Idamycin because generic idarubicin products have already entered the market. A Paragraph IV certification is most consequential when a generic applicant seeks approval before listed patents expire. That scenario no longer defines the U.S. idarubicin market.
Any current dispute would more likely involve:
- Manufacturing quality or supply continuity.
- ANDA approval or deficiency issues.
- Contracting and hospital purchasing.
- Product recalls.
- Patent claims limited to a particular formulation or manufacturing process.
- Intellectual-property disputes involving a combination product rather than idarubicin alone.
What formulation patents protect idarubicin?
Idamycin is an injectable formulation, and its main formulation risks are technical and regulatory rather than exclusivity-based. Manufacturers must control concentration, sterility, stability, container compatibility and handling requirements for a cytotoxic product.
Potential formulation barriers include:
- Lyophilized versus ready-to-use presentations.
- Preservative systems.
- Stability-enhancing excipients.
- Container closure systems.
- Low-volume concentrated solutions.
- Cold-chain and storage specifications.
- Extractables and leachables from vial components.
These issues can create manufacturing or approval costs, but they do not provide a durable commercial moat comparable to an active patent on a new molecular entity.
When does Idamycin lose exclusivity?
Idamycin lost practical U.S. exclusivity years ago. The product’s approval in 1990 places it well outside the period of patent and regulatory protection normally available to a new oncology medicine.[1]
A practical exclusivity timeline is:
| Period |
Event |
| 1990 |
FDA approval of idarubicin for adult AML |
| 1990s-2000s |
Development of international and generic markets |
| 2000s onward |
Broad generic availability in major markets |
| Current market |
Mature injectable generic with low originator protection |
| 2025-2030 |
Continued generic supply, price pressure and protocol substitution |
No major exclusivity event is expected to alter the U.S. market between 2025 and 2030.
Which companies are challenging Idamycin commercially?
Competition comes primarily from generic injectable manufacturers and alternative AML therapies rather than from a single high-profile patent challenger.
The competitive field includes:
- Generic idarubicin suppliers.
- Generic daunorubicin suppliers.
- Jazz Pharmaceuticals’ Vyxeos, a liposomal formulation of daunorubicin and cytarabine.
- AbbVie and Genentech’s Venclexta, used with hypomethylating agents or low-dose cytarabine in appropriate AML patients.
- Astellas’ Xospata for FLT3-mutated relapsed or refractory AML.
- Servier’s Tibsovo for IDH1-mutated AML.
- Bristol Myers Squibb’s Idhifa for IDH2-mutated AML.
- Other intensive chemotherapy combinations used in academic and community oncology settings.
Vyxeos has a differentiated formulation and indication profile, while venetoclax-based regimens compete by expanding lower-intensity treatment options for older or medically unfit patients.[4][5]
How does Idamycin compare with daunorubicin and Vyxeos?
| Product |
Core role |
Commercial position |
Main competitive advantage |
| Idamycin / idarubicin |
Intensive AML induction |
Mature generic |
Established use and low acquisition cost |
| Daunorubicin |
Intensive AML induction |
Mature generic |
Broad institutional familiarity |
| Vyxeos |
AML and therapy-related AML subsets |
Branded specialty product |
Liposomal delivery and differentiated label |
| Venetoclax combinations |
Lower-intensity AML treatment |
Branded, growing segment |
Use in patients unsuitable for intensive chemotherapy |
| Targeted AML drugs |
Biomarker-defined disease |
Branded specialty products |
Molecularly selected efficacy |
Idarubicin can retain volume where intensive induction remains the standard, but its revenue per treatment course is vulnerable to generic price competition. Vyxeos and targeted agents can displace idarubicin in defined clinical populations, while daunorubicin remains the closest direct substitute.
What is the Idamycin market size and revenue exposure?
Idamycin-specific global sales are not generally reported as a separate public revenue line. Pfizer’s financial reporting aggregates products into broader business segments and does not provide a dependable current Idamycin revenue figure.[6]
The addressable market is a narrow subsegment of hospital oncology spending:
- AML incidence is relatively low compared with common solid tumors.
- Idarubicin is used for a subset of patients receiving intensive chemotherapy.
- Generic prices are low relative to branded AML therapies.
- Hospital procurement creates substantial price variation by country and contract.
- Revenue is concentrated in institutional channels.
The commercial value of idarubicin is therefore driven more by treatment volume and supply reliability than by pricing power.
What is the Idamycin market projection through 2030?
The base-case projection is a low-single-digit annual decline in global value through 2030, with unit demand broadly stable or declining modestly.
| Scenario |
Unit trend through 2030 |
Price trend |
Value outlook |
| Base case |
0% to -2% annually |
-2% to -5% annually |
-3% to -6% annually |
| Downside |
-2% to -4% annually |
-4% to -8% annually |
-6% to -11% annually |
| Upside |
0% to +2% annually |
-1% to -3% annually |
-1% to +1% annually |
The base case assumes:
- Continued use of intensive AML induction.
- Stable idarubicin inclusion in national protocols.
- Ongoing generic competition.
- Gradual migration toward targeted and lower-intensity regimens.
- No major supply interruption.
- No new branded formulation that materially changes idarubicin’s positioning.
The upside case requires stronger AML diagnosis and treatment rates, increased use of intensive chemotherapy and supply constraints affecting competing anthracyclines. The downside case follows rapid adoption of venetoclax-based regimens, broader use of Vyxeos or targeted treatments, and additional generic price compression.
What generic launch risks exist for Idamycin?
Generic launch risk is already realized in the U.S. and other mature markets. The principal risk is not a future first generic launch but continued erosion from additional suppliers.
Commercial risks include:
- Hospital conversion from branded Idamycin to generic idarubicin.
- Tender-driven price reductions.
- Supplier exits after margin compression.
- Shortages caused by limited sterile-injectable manufacturing capacity.
- Quality-related recalls.
- Substitution by daunorubicin or newer AML regimens.
- Lower treatment intensity in older or medically frail patients.
Manufacturing is the most important practical barrier. Sterile cytotoxic injectables require validated aseptic processing, specialized containment, regulatory compliance and reliable active pharmaceutical ingredient supply. These requirements can limit the number of dependable suppliers even when legal market entry is unrestricted.
What patent litigation and settlement agreements affect Idamycin?
No major current U.S. patent litigation or settlement agreement is expected to materially restrict generic idarubicin access. The product’s commercial history is too mature for a conventional originator-versus-first-generic settlement to drive current market timing.
Any relevant litigation should be evaluated at the supplier level through:
- FDA ANDA records.
- Orange Book patent listings.
- Federal district court filings.
- Paragraph IV notices.
- Product liability and recall databases.
- Procurement and shortage notifications.
The strategic focus for investors and licensors should be supply continuity, manufacturing economics and clinical substitution rather than patent settlement timing.
Is there biosimilar risk for Idamycin?
Biosimilar risk does not apply directly. Idarubicin is a chemically synthesized small molecule, not a biologic. Generic-drug regulation under an ANDA pathway is the relevant competitive framework.
Biosimilar competition affects AML treatment indirectly through biologic supportive-care products and other oncology therapies. It does not create a separate biosimilar entry event for Idamycin.
What licensing deals involve Idamycin?
There is no current high-value licensing narrative centered on Idamycin. The product is a mature cytotoxic medicine with limited remaining intellectual-property value. Historic regional licensing and distribution arrangements may exist, but they are not expected to materially affect global market structure.
Current business-development value is more likely to arise from:
- Regional generic rights.
- Hospital supply contracts.
- Contract manufacturing.
- Sterile injectable portfolio acquisitions.
- Combination development involving newer AML agents.
- Licensing of delivery technologies that could reposition idarubicin.
A new commercial opportunity would require a differentiated delivery system, a clinically meaningful combination or a new indication. The conventional idarubicin injection alone has limited licensing attractiveness.
Key Takeaways
- Idamycin is idarubicin hydrochloride, an anthracycline approved for adult AML.
- The drug is used mainly with cytarabine in intensive induction regimens.
- Clinical trials now study idarubicin-containing regimens rather than the Idamycin brand.
- U.S. patent and regulatory exclusivity have expired.
- Generic competition is established, and Paragraph IV litigation has limited strategic relevance.
- No biosimilar pathway applies because idarubicin is a small molecule.
- The main commercial risks are price erosion, treatment substitution and sterile-injectable supply disruption.
- Idamycin-specific revenue is not separately disclosed by Pfizer.
- A reasonable base-case projection is a 3% to 6% annual decline in market value through 2030.
- The product retains clinical relevance but has weak patent strength and limited originator-market power.
FAQs About Idamycin and Idarubicin
Is Idamycin still used for AML?
Yes. Idarubicin remains an option for intensive AML induction, commonly in combination with cytarabine. Use depends on patient fitness, disease biology, institutional protocol and available alternatives.
Is Idamycin the same as daunorubicin?
No. Both are anthracyclines used in AML, but idarubicin and daunorubicin are different active ingredients with different dosing, pharmacologic properties and clinical evidence.
Can a generic company launch idarubicin without a patent license?
In the United States, an approved generic manufacturer can market idarubicin after satisfying FDA requirements and addressing any applicable listed patents. The core Idamycin exclusivity period has expired.
Does Vyxeos replace Idamycin in all AML patients?
No. Vyxeos is used in defined AML populations and has a different formulation and label. Idarubicin remains available for intensive chemotherapy protocols where clinicians select it.
What is the biggest long-term threat to idarubicin sales?
The largest threat is clinical substitution. Venetoclax-based regimens, targeted therapies and differentiated chemotherapy products can reduce the number of patients receiving conventional idarubicin-cytarabine induction.
References
- U.S. Food and Drug Administration. (2023). Idamycin PFS (idarubicin hydrochloride) injection prescribing information.
- National Cancer Institute. (n.d.). Adult acute myeloid leukemia treatment. National Cancer Institute.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2020). Vyxeos (daunorubicin and cytarabine) liposome prescribing information.
- U.S. Food and Drug Administration. (2024). Venclexta (venetoclax) prescribing information.
- Pfizer Inc. (2024). Annual report and Form 10-K.
